Status:
UNKNOWN
The Effect of Intraoperative Dexmedetomidine on Postoperative Morphine Requirements After Breast Cancer Surgery
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Morphine Consumption
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflamma...
Detailed Description
Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflamma...
Eligibility Criteria
Inclusion
- Patients who fulfill the criteria of breast cancer under general anesthesia.
Exclusion
- Major systemic disease, such as congestive heart failure, liver cirrhosis, end stage renal disease and malignancy.
- Patients who have the risk of difficult ventilation or intubation.
- Pregnant women.
- Coagulopathy.
Key Trial Info
Start Date :
April 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04454515
Start Date
April 20 2021
End Date
July 1 2025
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Cancer Center
Taipei, Taiwan, 106